REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals over allegations that the company made false and misleading statements regarding a Phase 3 clinical trial of Fianlimab for melanoma treatment. The trial failed to reach statistical significance on its primary endpoint, causing an $11 billion market cap loss. Investors claim Regeneron concealed flawed statistical assumptions and slow event rates while expressing confidence in the trial's success. The lead plaintiff deadline is September 14, 2026.

09/12/2026, 2:47 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the company's announcement on August 17, 2026, that its DURAVYU drug failed to meet primary endpoints in the LUGANO Phase 3 clinical trial for wet AMD treatment. The failure to demonstrate superiority over Regeneron's Eylea resulted in a 66.98% stock price decline, falling from approximately $14.75 to $4.87 per share.

09/08/2026, 5:52 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

Pomerantz Law Firm has filed class action lawsuits against Regeneron Pharmaceuticals, Capricor Therapeutics, and GPGI, Inc. for alleged securities fraud. The primary focus is on Regeneron, where a Phase III clinical trial for Fianlimab-Libtayo failed to meet its primary endpoint, causing the stock to decline significantly on two separate occasions in April and May 2026. Investors with losses are urged to contact the firm by September 14, 2026, to potentially become lead plaintiffs.

09/08/2026, 4:58 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Bloom Energy Corporation of Class Action Lawsuit and Upcoming Deadlines – BE

Pomerantz Law Firm has filed class action lawsuits against Bloom Energy Corporation, Primoris Services Corporation, and Regeneron Pharmaceuticals, Inc., alleging securities fraud and unlawful business practices. The Bloom Energy lawsuit was triggered by a Hunterbrook Media report alleging the company relies on Chinese scandium in its supply chain, causing the stock to fall 5.67% on July 8, 2026. Investors have until September 28, 2026, to request Lead Plaintiff status.

09/08/2026, 4:51 PM • GlobeNewswire

Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS Insider

The global atopic dermatitis drugs market is projected to grow from USD 15.92 billion in 2025 to USD 33.42 billion by 2035, driven by increased adoption of biologic therapies, JAK inhibitors, and novel treatments. North America leads with 36% market share, while Asia-Pacific shows the fastest growth. Biologics dominate with 42% market share, though high costs and JAK inhibitor safety warnings present challenges.

09/04/2026, 8:30 PM • GlobeNewswire

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.

09/04/2026, 2:30 PM • The Motley Fool

REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly making false and misleading statements about its Phase 3 clinical trial of Fianlimab for melanoma treatment. The company reportedly failed to disclose that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. After initially expressing confidence in the trial, Regeneron altered the trial protocol in November 2025 without timely disclosure and ultimately announced on May 15, 2026 that the trial failed to reach statistical significance, resulting in an $11 billion market cap loss.

09/02/2026, 6:36 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm showed no meaningful clinical differentiation from standard therapies, and the study was unlikely to achieve statistical significance on its primary endpoint. The class period covers purchases between August 1, 2025 and May 15, 2026.

09/02/2026, 12:00 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm showed no meaningful clinical differentiation from standard therapies, and the study was unlikely to achieve statistical significance on its primary endpoint. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are encouraged to join the case.

08/30/2026, 12:00 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm lacked meaningful clinical differentiation, and the study was unlikely to achieve statistical significance. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are eligible to join the case.

08/26/2026, 12:00 PM • GlobeNewswire

IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

08/21/2026, 7:02 AM • The Motley Fool

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens Berman

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals after its Phase 3 clinical trial for a melanoma therapy failed to reach statistical significance. The lawsuit alleges the company made false and misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the treatment arm was not achieving meaningful differentiation. The stock plunged following the May 15, 2026 announcement, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026.

08/05/2026, 8:34 PM • GlobeNewswire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors to join a class action lawsuit against Regeneron Pharmaceuticals for securities fraud. The company allegedly made false and misleading statements about its Phase III Fianlimab-Libtayo study, claiming it was likely to succeed when it actually failed to demonstrate clinical differentiation from competing therapies. Investors who purchased securities between August 1, 2025 and May 15, 2026 are encouraged to participate before the September 14, 2026 deadline.

08/04/2026, 10:55 AM • GlobeNewswire

REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made false statements about trial progress while concealing that preliminary statistical assumptions were flawed and the treatment showed no meaningful differentiation over standard therapies. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026.

08/03/2026, 8:50 PM • GlobeNewswire

$REGN Securities: Suffer Losses on Your Regeneron Investment? BFA Law Reminds Investors of the Securities Fraud Lawsuit to Recover Losses

A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly misleading investors about the success of its Phase III Fianlimab-Libtayo clinical trial. The stock dropped 6.2% on April 29, 2026, and 9.8% on May 15, 2026, after the company announced the study failed to achieve statistical significance. Investors have until September 14, 2026, to request lead plaintiff status.

07/31/2026, 6:46 AM • GlobeNewswire